iTAC Software receives the 2023 Company of the Year Award
iTAC Software was identified as best in class in the global medtech and life sciences industry and leads the market with its iTAC.MOM.Suite, a solution with comprehensive performance and flexibility, offering the productivity and real-time management that customers require. The company addresses this market gap with a strong leadership focus that incorporates customer-centric strategies and exemplifies best practices implementation. Experts support customers through every stage of the product lifecycle, ensuring maximum availability and expertise.*
Each year, Frost & Sullivan presents a "Company of the Year Award" to the organization that demonstrates outstanding performance in terms of growth strategy and execution in its field. The award recognizes a high level of innovation in products and technologies and the resulting leadership position in terms of customer value and market penetration. The industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry. iTAC Software excels in the following criteria in the medtech and life sciences industry:
Adressing unmet needs
Implementation of best practices
Customer purchase experience
Brand equity
Award report
The iTAC.MOM.Suite is a comprehensive system that combines MES functions with solutions for controlling, optimizing, and forecasting production processes in real time. It covers all shopfloor processes and offers interfaces to higher-level systems, e.g., enterprise resource planning (ERP) and product lifecycle management (PLM), for interoperability. The solution is built on an open and service-oriented architecture, allowing it to integrate into existing system landscapes seamlessly. The award writeup provides an overview of the MedTech market, gives a short company background and then outlines how iTAC Software successfully leads the market with the MES/MOM solution iTAC.MOM.Suite.
*Frost & Sullivan 2024